The global dialysis equipment market size was USD 78.60 billion in 2023, and is calculated at

USD 84.65 Billion in 2024.

The market is projected to reach

USD 177.74 Billion by 2034

, and register a revenue

7.7%

over the forecast period (2025-2034).

Premium Insights:

Global diabetes drugs market has been registering rapid revenue growth driven by key factors, including increasing prevalence of diabetes worldwide, advancements in drug formulations, and rising awareness about diabetes management. Other factors driving revenue growth of the market is rising prevalence of type-2 diabetes in children and adolescents, and with oral treatment options remaining limited for this population, leading companies are developing drugs and treatments for pediatric patients living with type-2 diabetes. This is currently a focal point in the US, and is expected to extend to even more patients in other regions and countries, and will present need to cater to unmet needs in a sizable market segment. Moreover, ongoing development of innovative therapies such as GLP-1 receptor agonists and SGLT-2 inhibitors, and increasing emphasis on personalized medicine and digital health technologies, including Continuous Glucose Monitoring (CGM) and telehealth services. These innovations are transforming diabetes care and driving patient engagement. Also, government initiatives promoting early diagnosis and preventive measures are contributing to rising awareness and focus on diabetes management.

Rising prevalence of diabetes continues to remain a global concern, with prevalence rates expected to increase substantially between 2025 and 2045. According to estimates by the International Diabetes Federation (IDF), around 537 million adults aged 20–79 years are living with diabetes worldwide, including those with both type 1 and type 2 diabetes, and diagnosed and undiagnosed cases. In addition, the number of adults with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

Diabetes drugs play a critical role in managing blood sugar levels for patients with type 1 and type 2 diabetes. These medications include insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, and metformin, each targeting different pathways to control glucose levels. Insulin remains essential for type 1 diabetes management, while newer classes, such as GLP-1 receptor agonists, offer significant benefits for type 2 diabetes by promoting weight loss and reducing cardiovascular risks. Recent advancements in drug delivery systems, such as insulin pumps and continuous glucose monitoring systems, have enhanced patient convenience and treatment effectiveness. Also, novel oral formulations and extended-release injections improve compliance by reducing dosing frequency.

Some key trends in the market include integration of digital health tools, such as mobile apps that sync with CGMs for real-time monitoring and personalized treatment adjustments. Ongoing research into novel biomaterials and encapsulation technologies promises further improvements in drug stability and efficacy. With the growing prevalence of diabetes worldwide, particularly in emerging economies, the demand for innovative, patient-friendly medications is expected to rise. Interest in biosimilars is also increasing for treatment of diabetes, and offers potential of cost-effective alternatives to traditional insulin therapies. Overall, diabetes drugs are evolving rapidly, with advancements aimed at improving patient outcomes, simplifying treatment, and addressing unmet clinical needs.

{{bar_graph}}

Top Diabetes Drugs Market Drivers and Trends:

• 
  

  Rising Prevalence of Diabetes Worldwide:

  
  

  Factors such as rapidly aging populations, sedentary lifestyles, increasing rates of obesity, and primarily rising prevalence of diabetes are driving growth of the global diabetes drugs market. Diabetic patient bases, especially in emerging markets such as Asia Pacific and Latin America, have been expanding significantly in recent times and this is driving demand for more affordable and effective drugs to address needs and aid in management of the disease.

• 
  

  Technological Advancements in Diabetes Treatments

  
  

  : Development of innovative drug formulations like GLP-1 receptor agonists and SGLT-2 inhibitors, are improving patient outcomes, and supporting adoption of newer therapies. Also, artificial pancreas systems, which are closed-loop systems that mimic the natural function of the pancreas, and combine continuous glucose monitoring with an insulin pump to automatically adjust insulin delivery based on real-time glucose levels, are gaining traction. Devices like Medtronic’s MiniMed 780G and Tandem’s Control-IQ have been game-changers in improving glucose control and reducing hypoglycemia risk. In addition, technological advancements in smart insulin pens, oral GLP-1 receptor agonists, wearable tech and CGMs, and non-invasive glucose monitoring solutions using electromagnetic signals or light sensors to measure glucose levels, among other advancing technologies are expected to support growth of the diabetes drugs market over the forecast period.

• 
  

  Easy Healthcare Access:

  
  

  Access to healthcare in developing regions is becoming increasingly simple and cost-effective, thus allowing for more patients to access both essential insulin therapies and advanced diabetes drugs. Also, easy access to services and rising awareness regarding the benefits of regular check-ups are supporting trends of preventive healthcare and early diagnosis for various diseases. These trends are further supported by government initiatives and awareness campaigns, and serving to drive demand for diabetes management solutions as more patients seek timely interventions.

• 
  

  Digital Health Technologies:

  
  

  Integration of digital health technologies such as continuous glucose monitoring (CGM) systems and mobile health apps is serving to enhance patient adherence and management, thus creating greater demand for complementary diabetes therapies. As more patients and healthcare providers adopt these technologies, the use of advanced diabetes drugs is expected to expand and support growth of the global diabetes drugs market.

Diabetes Drugs Market Restraining Factor Insights

• 
  

  High Cost of Diabetes Drugs:

  
  

  Diabetes drugs, particularly insulin and newer medications like GLP-1 receptor agonists, come at a high cost and this can limit accessibility for patients, especially in low-income regions. Affordability issues can reduce patient adherence and limit market expansion to a major extent.

• 
  

  Complex Research and Development:

  
  

  Developing diabetes drugs involves complex and costly research, including lengthy clinical trials to prove safety and efficacy. Regulatory hurdles and increasing scrutiny over drug approval processes can delay product launches, thereby impacting revenue growth.

• 
  

  Side Effects and Disadvantages:

  
  

  Some diabetes drugs, such as SGLT-2 inhibitors, are associated with side effects like urinary tract infections, while others may cause weight gain or hypoglycemia. These disadvantages may deter some patients or healthcare providers and restrain potential of wider adoption of certain drugs.

• 
  

  Competition from Biosimilars and Generics:

  
  

  Increasingly easier availability of biosimilars and generic versions of diabetes medications can result in major pharmaceutical companies considering lowering prices of diabetes drugs and reducing profit margins, thereby potentially limiting revenue growth in established markets.

• 
  

  Changing Lifestyle Habits and Preventative Measures:

  
  

  Increased awareness and emphasis on lifestyle changes, such as diet and exercise, to prevent or manage type 2 diabetes could reduce reliance on and need for pharmacological treatments. Also, advancements in non-drug therapies, such as bariatric surgery, may reduce the demand for diabetes medications in some patient populations. This can have a moderate impact on growth of the diabetes drugs market.

Diabetes Drugs Market Opportunities

• 
  

  Expansion into Emerging Markets:

  
  

  Expansion into emerging markets can offer significant revenue potential. With prevalence of diabetes rising in regions such as Asia Pacific and Latin America, manufacturers can tap into growing demand by offering affordable, locally adapted therapies and capitalizing on government healthcare initiatives. Expanding product portfolios and engaging in local partnerships can further strengthen market presence.

• 
  

  Innovative Drug Formulations and Delivery Systems:

  
  

  Major companies can invest in development of innovative drug formulations and delivery systems to address evolving patient needs and further establish market position. Manufacturers can develop next-generation therapies, such as once-weekly GLP-1 receptor agonists or oral insulin, which improve patient compliance and outcomes. Collaborating with digital health platforms to integrate continuous glucose monitoring systems and smart insulin pumps can differentiate products and create additional revenue streams.

{{dialog}}

Diabetes Drugs Market Segmentation:

By Drug Class:

• Insulin
• GLP-1 Receptor Agonists
• SGLT-2 Inhibitors
• DPP-4 Inhibitors
• Biguanides (Metformin)
• Others (Thiazolidinediones, Meglitinides)

By Diabetes Type:

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Route of Administration:

• Oral
• Injectable
• Subcutaneous
• Intravenous

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

Segment Insights:

By Drug Class:

Insulin segment is expected to account for largest revenue share in the global diabetes drugs market. This can be attributed to essential role insulin plays in managing type 1 diabetes, where patients require daily insulin injections to regulate blood sugar levels. Also, increasing number of patients with type 2 diabetes becoming insulin-dependent due to disease progression is supporting demand. Advancements in insulin formulations, such as long-acting insulins such as insulin glargine and ultra-rapid formulations, offer better glycemic control, reducing the risk of complications. Moreover, increasing awareness and availability of insulin pumps and pen devices have improved patient adherence, contributing to market growth.

By Diabetes Type:

Type 2 diabetes segment is expected to continue to account for largest revenue share due to the sheer volume of patients globally, driven by increasing obesity, sedentary lifestyles, and aging populations. Type 2 diabetes management often requires a combination of therapies, including oral medications and, in advanced cases, insulin. The introduction of newer drug classes such as GLP-1 receptor agonists and SGLT-2 inhibitors, which offer additional cardiovascular and renal benefits, is also supporting adoption. Also, rising awareness and early diagnosis initiatives are contributing to market growth.

By Route of Administration:

Oral segment is expected to account for largest revenue share among the route of administration segments over the forecast period. Oral medications like metformin, SGLT-2 inhibitors, and DPP-4 inhibitors are highly preferred due to ease of use, lower costs, and ability to be taken without injections. The convenience of oral therapies makes them attractive for long-term management of diabetes, encouraging higher patient adherence. As more innovative oral formulations enter the market, such as oral GLP-1 receptor agonists, the demand for oral diabetes drugs is expected to rise significantly.

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool:

Vantage Point

By Distribution Channel:

Retail pharmacies segment among the distribution segments is expected to lead in terms of revenue share over the forecast period. Accessibility and high presence of retail pharmacies make this channel widely popular among patients to purchase diabetes medications. As diabetes becomes a chronic condition managed primarily in outpatient settings, patients prefer local retail pharmacies for convenient refills. Also, retail pharmacies provide easier access to both prescription and over-the-counter diabetes drugs, enhancing patient compliance. The growth of mail-order and online pharmacy services offered by retail chains is also expected to support revenue of this segment.

Regions and Countries

North America

• United States
• Canada
• Mexico
  

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India

Rest of Asia Pacific

• Latin America
• Brazil
• Argentina

Rest of Latin America

• Middle East & Africa
• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

Diabetes Drugs Market Regional Landscape:

North America leads among the regional diabetes drugs markets, driven primarily by factors such as high prevalence of diabetes, advanced healthcare infrastructure, and easy availability of innovative therapies. The US is the largest country-level market in terms of revenue share and volume consumption due to strong focus on Research and Development (R&D), rapid adoption of new drug technologies, and a large diabetic population.

Asia Pacific diabetes drugs markets is expected to register fastest revenue growth rate, driven by major contribution from China and India, where prevalence of diabetes is high and rising due to lifestyle changes and habits, urbanization, and rising obesity rates. Also, increasing healthcare investments, improving access to diabetes medications, and expanding awareness campaigns are supporting growth of the diabetes drugs markets in the region.

In the Europe diabetes drugs markets, Germany and the UK remain major markets for diabetes drugs. This is attributed to well-established healthcare systems and robust focus on early diagnosis and preventive care. Also, increasing government initiatives and favorable reimbursement policies for diabetes management in these countries is supporting growth of the market in the region. In the Latin America diabetes drugs markets, Brazil and Mexico lead in terms of revenue contribution, due to rising prevalence of diabetes and improving access to modern treatments. In the Middle East and Africa, Saudi Arabia and South Africa are key revenue contributors, where rising healthcare infrastructure and government efforts to manage diabetes are supporting market growth.

Diabetes Drugs Market

Competitive Landscape:

Company List:

• Novo Nordisk
• Sanofi
• Bristol Myers Squibb
• Eli Lilly and Company
• AstraZeneca
• Merck & Co.
• Johnson & Johnson
• Pfizer
• Novartis
• Boehringer Ingelheim
• AbbVie
• Teva Pharmaceuticals
• Glenmark Pharmaceuticals
• Lupin Pharmaceuticals
• Mylan N.V. (now part of Viatris)
  

Competitive Landscape:

The competitive landscape in the global diabetes drugs market is highly dynamic, with major pharmaceutical companies deploying various strategies and approaches to maintain an edge while expanding consumer base. Major companies such as Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca hold leading positions with broad portfolios of diabetes treatments. Major companies are continuously investing in research and development to introduce innovative therapies, such as next-generation insulin formulations, GLP-1 receptor agonists, and SGLT-2 inhibitors. Focus on developing therapies that offer additional benefits, such as cardiovascular protection and weight management, are also enabling companies to differentiate their products and attract a wider patient base.

In addition, leading companies are adopting strategic collaborations and partnerships to leverage each others strengths in R&D and expand into new geographic markets. Companies are also focusing on mergers and acquisitions to strengthen their product portfolios and enter high-growth regions. Furthermore, many are engaging in digital health integrations, including partnerships with technology companies to combine diabetes treatments with digital tools like continuous glucose monitoring systems, mobile apps, and telehealth services. Affordable pricing and introduction of biosimilars, particularly in emerging markets where cost-effective treatments are in high demand, is another focus area.

Recent Developments

• 
  

  August 1, 2024:

  
  

  Sanofi confirmed that it will be spending USD 1.4 Billion on a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany. The French drugmaker will be setting up the new plant at its existing site in Frankfurt, where it produces insulin brand Lantus. With this investment, Sanofi will replace its current insulin production plant with the construction of a 36,000-square-metre facility, and the projects is proposed to be completed by 2029. The objective of this endeavor is to secure the long-term supply of insulin for diabetic patients and ‘strengthen European security of supply’, and also strengthen the company’s commitment to be one of the world’s largest insulin manufacturers.

• 
  

  June 12, 2024:

  
  

  AstraZeneca was granted approval for its FARXIGA (dapagliflozin) by the US Food and Drug Administration (FDA). The drug is designed to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. FDA approval was based on positive results from the pediatric T2NOW Phase III trial, and FARXIGA was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycemic control. FARXIGA is a first-in-class, oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor, and had earlier been approved in 126 countries, including the EU.

• 
  

  May 17, 2024:

  
  

  Eli Lilly reported positive outcomes from Phase III QWINT-2 and QWINT-4 clinical trials of insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The once-weekly insulin efsitora alfa demonstrated during trials achievement of a non-inferior A1C reduction versus daily basal insulins, which are commonly used worldwide. The QWINT-2 trial targeted insulin-naïve patients while QWINT-4 included individuals requiring multiple daily insulin injections. QWINT-2 compared the efficacy and safety of efsitora to once-daily insulin degludec over 52 weeks. The trial also aimed to evaluate the performance of efsitora in patients both using and not using GLP-1 receptor agonists..

Frequently Asked Questions:

Q: What is the global diabetes drugs market size in 2024 and what is the projection for 2034?

A: The global diabetes drugs market size was calculated at USD 84.65 billion 2024 and expected to reach USD 177.74 billion in 2034

Which regional market accounted for largest revenue share in 2023, and what is the expected trend over the forecast period?

A: North America accounted for largest revenue share in 2023, and is also expected to continue to maintain dominance over the forecast period.

Q: Which are the major companies are included in the global diabetes drugs market report?

A: Major companies in the market report are Abbott Laboratories, Dexcom Inc., Medtronic PLC, Roche Holding AG, LifeScan Inc., Senseonics Holdings, Inc., Ascensia Diabetes Care, Arkray Inc., Sinocare Inc., Menarini Diagnostics S.r.l, Ypsomed AG, Nemaura Medical Inc., i-Sens Inc., Medtrum Technologies, Omron Healthcare Inc.

Q: What is the projected revenue CAGR of the global diabetes drugs market over the forecast period?

A: The global diabetes drugs market is expected to register a CAGR of 7.7% between 2025 and 2034.

Q: What are some key factors driving revenue growth of the diabetes drugs market?

A: Some key factors driving market revenue growth are rising global prevalence of diabetes, rise in obesity rates, increasing rates of Polycystic Ovary Syndrome (PCOS), sedentary lifestyles, rapidly aging population, increasing health awareness among individuals, and growing preventive healthcare trend.